TVB-2640 for Non-Small Cell Lung Cancer
Trial Summary
What is the purpose of this trial?
This is a prospective one-arm, two-stage phase 2 trial of TVB-2640 in KRAS mutant NSCLC patients. 13 patients will be treated with a minimum of 1 cycle of TVB-2640 therapy over 8 weeks.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot use strong CYP3A4/5 agonists or inhibitors during the study. It's best to discuss your current medications with the study team to ensure they don't interfere with the trial.
Research Team
David Gerber, MD
Principal Investigator
Professor
Eligibility Criteria
This trial is for adults with advanced stage Non-Small Cell Lung Cancer (NSCLC) that has a specific KRAS mutation and has worsened despite previous treatments including chemotherapy and immune therapy. Participants must have good organ function, no severe heart disease or infections, not be pregnant, and agree to use contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive TVB-2640 100mg/m2 orally once a day for 8 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Extension
Patients with stable disease or partial/complete remissions will continue therapy
Treatment Details
Interventions
- TVB-2640
Find a Clinic Near You
Who Is Running the Clinical Trial?
David E Gerber
Lead Sponsor
Gateway for Cancer Research
Collaborator
Sagimet Biosciences Inc.
Industry Sponsor
Cancer Prevention Research Institute of Texas
Collaborator